Patents by Inventor Ulrike Bauder-Wust

Ulrike Bauder-Wust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
    Patent number: 11951190
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11931430
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS
    Publication number: 20230406847
    Abstract: The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.
    Type: Application
    Filed: November 11, 2021
    Publication date: December 21, 2023
    Applicant: ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
    Inventors: Alexander HOEPPING, Hans-Joachim LANKAU, Ronny HESSE, Klaus KOPKA, Ulrike BAUDER WÜST, Christian LIS, René SMITS, Jan MOLLITOR, Kristine SCHEIBE, Alexandra GEISSLER
  • USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20210283279
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: January 7, 2021
    Publication date: September 16, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20210177996
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190374660
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 26, 2019
    Publication date: December 12, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10471160
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: November 12, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova, Hans-Christian Kliem, Clemens Kratochwil
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190336622
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 12, 2019
    Publication date: November 7, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10398791
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 3, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190060491
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 28, 2018
    Publication date: February 28, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190008988
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 18, 2018
    Publication date: January 10, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA, Hans-Christian KLIEM, Clemens KRATOCHWIL
  • 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10016519
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 10, 2018
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRIUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Klaus Kopka, Martina Benesova, Jens Cardinale, Matthias Eder, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut
  • 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20170246327
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
    Type: Application
    Filed: March 20, 2017
    Publication date: August 31, 2017
    Inventors: Klaus KOPKA, Martina Benesova, Jens Cardinale, Matthias Eder, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe Haberkorn, Michael Eisenhut
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20160228587
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS
    Publication number: 20090130020
    Abstract: This invention relates to novel compounds F-18 radio-labeled amino-alcohols suitable for labeling or already labeled by 18F methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
    Type: Application
    Filed: September 11, 2008
    Publication date: May 21, 2009
    Inventors: Lutz Lehmann, Mathias Berndt, Dietmar Berndorff, Sabine Zitzmann-Kolbe, Ulrike Bauder-Wust, Martin Schafer, Uwe Haberkorn, Michael Eisenhut, Armin Runz
  • Polyamine-substituted ligands for use as contrast agents
    Publication number: 20070202047
    Abstract: The present invention relates to a polyamine-substituted ligand for the preparation of a contrast agent derived from a chelating molecule selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylentriamine-pentaacetic acid (DTPA), wherein at least one of the carboxylic groups of the chelating molecule is reacted with an amine of formula HNR1R2 to form an amide bond, wherein R1, R2 are independently selected from the group consisting of H; (CH2)n—NR3R4; and R5; R3, R4 are independently selected from the group consisting of H; (CH2)m—NR6R7; and (CH2)m-1—CH3; R6, R7 are independently selected from the group consisting of H; and (CH2)o-1—CH3; n, m, o are independently 2, 3, or 4; R5 is of formula and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R1, R2 is other than H.
    Type: Application
    Filed: January 4, 2007
    Publication date: August 30, 2007
    Inventors: Markus Wolf, Ulrike Bauder-Wust, Uwe Haberkorn, Michael Eisenhut, Walter Mier